Navigation Links
Selexis and Neogenix Oncology Announce Agreement on Antibody Project
Date:9/22/2009

GENEVA and GREAT NECK, N.Y., Sept. 22 /PRNewswire/ -- Selexis SA ("Selexis") and Neogenix Oncology, Inc. ("Neogenix") today jointly announced a Research Services Agreement for the rapid development of a high-performance CHO based production cell line expressing an undisclosed Neogenix antibody. The cell line will be developed by Selexis scientists utilizing the industry leading Selexis SURE Cell Line Development(TM) Platform.

"We are very appreciative to have this opportunity to establish a strong partnership with the world class scientists at Neogenix as the company develops innovative therapies for the management of serious and difficult to treat cancers," said Dr Igor Fisch, CEO and co-founder of Selexis SA. "By targeting antigens shown only to be associated with tumor cells, Neogenix is in a unique position with regards to treating cancer, making this a very special program to us."

"After careful consideration Neogenix chose Selexis for this important project based on their industry reputation and proven record of performance in being able to quickly generate production cell lines to support high demand antibody programs like ours," said Dr. Andrew Bristol, Vice President of Research and Development of Neogenix.

Neogenix Oncology, Inc. announced last week that the Food and Drug Administration (FDA) has granted permission for the company to begin a Phase I trial with its first therapeutic antibody, NPC-1C under its first IND (Investigational New Drug Application). This first human trial will evaluate the safety of NPC-1C in patients with late stage pancreatic or colorectal cancer. The project being undertaken with Selexis will make an important contribution toward the development and potential commercialization of this and other potential Neogenix products.

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

About Neogenix Oncology, Inc.

Founded in 2004, Neogenix Oncology, Inc., headquartered in Great Neck, NY, is a research-driven biopharmaceutical company that develops and commercializes innovative diagnostics and therapeutics for the management of solid tumors. Neogenix's pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Great Neck, NY and in Rockville, MD. For more information, please visit the company's website at www.neogenixoncology.com.


'/>"/>
SOURCE Selexis SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Selexis and NKT Therapeutics Enter Into Research Services Agreement
2. Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree
3. US Oncology Named to InformationWeek 500 as Top User of Business Technology
4. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
5. ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice
6. NCCN Holds Oncology Research Best Practices Conference
7. CBI Announces Multi-Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum
8. DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop
9. Managing Myeloma Website Launches an Interactive Forum for Oncology Nurses, Wins 2009 Gold Hermes Creative Award for Site Overall
10. Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine(TM) For Prostate Conditions With Start-Up of Phase 2 BPH Trial
11. Arizona Oncology Opens Radiation Facility at Phoenix Baptist Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 2016 , ... May 26, 2016- In search of the K. Warriors, Shaolin ... of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West ... and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is ...
(Date:5/27/2016)... ... 27, 2016 , ... Southland Log Homes , designer and manufacturer of ... kits, which can be found on its website at SouthlandLogHomes.com. , The designs of ... they highlight the craftsmanship of timber post and beam construction. The result is ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... With over ... to walk, the demand for a sustainable product to aid in the rehabilitation process ... aid in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
Breaking Medicine Technology: